DarioHealth (DRIO)
Market Price (12/28/2025): $10.28 | Market Cap: $32.3 MilSector: Health Care | Industry: Health Care Technology
DarioHealth (DRIO)
Market Price (12/28/2025): $10.28Market Cap: $32.3 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Telehealth Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -169% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -40 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -161% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.4%, Rev Chg QQuarterly Revenue Change % is -33% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 40% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -108%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -109% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 1980% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -138% | ||
| High stock price volatilityVol 12M is 2026% | ||
| Key risksDRIO key risks include [1] substantial doubt about its ability to continue as a going concern due to significant operating losses and a breached financial covenant, Show more. |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Telehealth Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -169% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -40 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -161% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -2.4%, Rev Chg QQuarterly Revenue Change % is -33% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 40% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -108%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -109% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 1980% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -138% |
| High stock price volatilityVol 12M is 2026% |
| Key risksDRIO key risks include [1] substantial doubt about its ability to continue as a going concern due to significant operating losses and a breached financial covenant, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
<b>1. Strong Financial Performance and Strategic Acquisition</b><br><br>
DarioHealth reported full-year 2024 revenue of $27 million, marking a 32.9% increase from 2023, and reduced its losses by 45.15% to -$30.09 million. This improvement in financial profile was significantly bolstered by the transformational acquisition of Twill in Q1 2024, which was immediately accretive to revenues, gross margins, and go-to-market strategy.<br><br>
<b>2. Expansion of GLP-1 Solution</b><br><br>
The company made meaningful progress with its Dario GLP-1 Behavioral Change Program, showing significant interest and adoption among commercial clients. In January 2025, DarioHealth further expanded its GLP-1 solution by adding prescribing capabilities through a partnership with MediOrbis, targeting both employers and direct-to-consumer markets.<br><br>
<b>3. Growth in B2B2C Channel and New Employer Contracts</b><br><br>
DarioHealth experienced substantial growth in its core B2B2C (Business-to-Business-to-Consumer) recurring revenues, which increased 300% to $20 million in 2024 compared to $5 million in 2023. The company also signed four new employer contracts in November 2024, across its full product suite, which are expected to go live and contribute to recurring revenue in the first quarter of 2025.<br><br>
<b>4. Strategic Partnership for Fall Risk Assessment</b><br><br>
In October 2025, DarioHealth announced a strategic collaboration with OneStep to integrate smartphone-based fall risk assessment technology into its digital health platform. This partnership aims to provide proactive fall risk identification for high-risk populations, leveraging OneStep's FDA-listed motion-analysis technology.<br><br>
<b>5. Expanded Pharma Collaborations</b><br><br>
DarioHealth expanded its pharma collaborations in November 2024 with a new contract with a global pharmaceutical leader. This collaboration utilizes Dario Connect (formerly Twill Care) to enhance user engagement for specific patient populations, transitioning the business model from milestone-based to recurring service subscription fees.
Show moreStock Movement Drivers
Fundamental Drivers
The -24.3% change in DRIO stock from 9/27/2025 to 12/27/2025 was primarily driven by a -26.5% change in the company's Shares Outstanding (Mil).| 9272025 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 13.27 | 10.04 | -24.34% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 27.15 | 24.73 | -8.90% |
| P/S Multiple | 1.21 | 1.27 | 5.02% |
| Shares Outstanding (Mil) | 2.48 | 3.14 | -26.46% |
| Cumulative Contribution | -29.64% |
Market Drivers
9/27/2025 to 12/27/2025| Return | Correlation | |
|---|---|---|
| DRIO | -24.3% | |
| Market (SPY) | 4.3% | 18.3% |
| Sector (XLV) | 15.2% | 0.4% |
Fundamental Drivers
The -25.1% change in DRIO stock from 6/28/2025 to 12/27/2025 was primarily driven by a -32.5% change in the company's Shares Outstanding (Mil).| 6282025 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 13.40 | 10.04 | -25.07% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 28.03 | 24.73 | -11.78% |
| P/S Multiple | 1.13 | 1.27 | 12.52% |
| Shares Outstanding (Mil) | 2.37 | 3.14 | -32.49% |
| Cumulative Contribution | -32.98% |
Market Drivers
6/28/2025 to 12/27/2025| Return | Correlation | |
|---|---|---|
| DRIO | -25.1% | |
| Market (SPY) | 12.6% | 4.1% |
| Sector (XLV) | 17.0% | -4.9% |
Fundamental Drivers
The -27.8% change in DRIO stock from 12/27/2024 to 12/27/2025 was primarily driven by a -55.3% change in the company's Shares Outstanding (Mil).| 12272024 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 13.90 | 10.04 | -27.77% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 23.05 | 24.73 | 7.29% |
| P/S Multiple | 1.22 | 1.27 | 4.54% |
| Shares Outstanding (Mil) | 2.02 | 3.14 | -55.28% |
| Cumulative Contribution | -49.85% |
Market Drivers
12/27/2024 to 12/27/2025| Return | Correlation | |
|---|---|---|
| DRIO | -27.8% | |
| Market (SPY) | 17.0% | 2.0% |
| Sector (XLV) | 13.8% | -2.3% |
Fundamental Drivers
The -85.8% change in DRIO stock from 12/28/2022 to 12/27/2025 was primarily driven by a -173.2% change in the company's Shares Outstanding (Mil).| 12282022 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 70.60 | 10.04 | -85.78% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 26.88 | 24.73 | -7.97% |
| P/S Multiple | 3.02 | 1.27 | -57.78% |
| Shares Outstanding (Mil) | 1.15 | 3.14 | -173.20% |
| Cumulative Contribution | -128.44% |
Market Drivers
12/28/2023 to 12/27/2025| Return | Correlation | |
|---|---|---|
| DRIO | -71.8% | |
| Market (SPY) | 48.0% | 2.2% |
| Sector (XLV) | 17.9% | -1.5% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DRIO Return | 118% | -9% | -67% | -60% | -54% | -36% | -92% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| DRIO Win Rate | 58% | 50% | 17% | 42% | 33% | 25% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| DRIO Max Drawdown | -47% | -27% | -73% | -77% | -62% | -97% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | DRIO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.7% | -25.4% |
| % Gain to Breakeven | 2942.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -64.1% | -33.9% |
| % Gain to Breakeven | 178.3% | 51.3% |
| Time to Breakeven | 134 days | 148 days |
| 2018 Correction | ||
| % Loss | -95.7% | -19.8% |
| % Gain to Breakeven | 2207.7% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
DarioHealth's stock fell -96.7% during the 2022 Inflation Shock from a high on 2/12/2021. A -96.7% loss requires a 2942.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe DarioHealth:- A **Teladoc Health** for personalized, AI-driven chronic condition management (diabetes, hypertension, MSK).
- Like **Noom**, but for managing multiple serious chronic conditions (diabetes, hypertension, MSK) with an AI-powered platform and personalized coaching.
- A digital, AI-enhanced **Weight Watchers (WW)** program for a wide range of chronic health conditions beyond just weight management.
AI Analysis | Feedback
- Dario Chronic Condition Management Platform: A comprehensive digital health platform offering personalized coaching, real-time insights, and connected devices to help individuals manage multiple chronic health conditions.
- Diabetes Management Program: A digital program providing connected blood glucose monitoring, personalized coaching, and educational resources for individuals with diabetes.
- Hypertension Management Program: A digital program featuring connected blood pressure monitoring, personalized coaching, and lifestyle guidance for individuals managing high blood pressure.
- Weight Management Program: A digital program that includes connected smart scales, personalized coaching, and nutritional guidance to support healthy weight loss and maintenance.
- Behavioral Health Program: A digital program providing access to mental health coaching, licensed therapists, and self-guided tools to support mental well-being and address behavioral health challenges.
AI Analysis | Feedback
DarioHealth (DRIO) primarily sells its digital health solutions to other companies, rather than directly to individuals. According to DarioHealth's public filings (such as their annual 10-K reports), the company states that it has a diverse customer base and does not depend on any single customer for a material portion of its revenue. Therefore, no individual company is publicly identified as a "major customer" accounting for a significant percentage of their overall revenue.
Instead, DarioHealth's customer base is comprised of various organizations across key segments within the healthcare ecosystem. These major customer categories, which represent the types of companies DarioHealth sells to, include:
- Health Plans and Payers: These are insurance companies, self-funded employers, and other entities that provide health benefits. They contract with DarioHealth to offer its digital therapeutics platform to their members or beneficiaries as a covered benefit.
- Employers: Companies directly contract with DarioHealth to provide DarioHealth's chronic condition management programs to their employees as part of their corporate wellness or benefits programs.
- Strategic Partners: This category includes a variety of entities such as benefits consultants, pharmacy benefit managers (PBMs), other healthcare technology providers, and healthcare systems that either resell DarioHealth's solutions or integrate them into broader service offerings.
While DarioHealth does not disclose the names of specific individual customer companies within these categories due to the distributed nature of its client base and confidentiality agreements, these represent the primary types of organizations that purchase and utilize DarioHealth's services.
AI Analysis | Feedback
nullAI Analysis | Feedback
Erez Raphael, Chief Executive Officer
Erez Raphael has served as the CEO and a Director of DarioHealth since August 2013. He is also a co-founder of DarioHealth. Mr. Raphael possesses over 17 years of experience in the software industry, with expertise spanning software development, product management, and software portfolio management. He co-founded redB LTD in early 2011, which launched mySuper.co.il, a prominent e-commerce platform for supermarkets in Israel. Prior to becoming CEO, he was DarioHealth's VP Product and R&D, and he has held leadership roles at Amdocs and Nokia Siemens Networks.
Chen Franco-Yehuda, Chief Financial Officer, Treasurer, and Secretary
Chen Franco-Yehuda assumed the role of Chief Financial Officer, Treasurer, and Secretary at DarioHealth on May 15, 2025. She brings extensive financial leadership experience, particularly within the healthcare and life sciences sectors. Previously, she served as CFO, Treasurer, and Secretary at Pluri Inc., a global biotech company. In this role, she was responsible for financial strategy, investor relations, legal affairs, and significant cross-border transactions, including securing substantial capital through various fundraising rounds and driving merger and acquisition activities. Ms. Franco-Yehuda was honored with the Israeli CFO Excellence Award in January 2025. Her career began as an Audit/Assurance Manager at PwC, and she is a licensed CPA in Israel.
Rick Anderson, President & General Manager, North America
Rick Anderson joined DarioHealth as President and General Manager of North America from Catasys, Inc. (later OnTrak, Inc.), where he spent nearly 12 years. At Catasys, he served as President, Chief Operating Officer, and a board member, building and scaling the business to tens of millions in recurring revenue and securing agreements with major U.S. health plans. He led Catasys from its conceptual stage to an approximate $500 million market capitalization. His prior experience includes being a Senior Executive Vice President at Hythiam, Inc., a predecessor to Catasys, Inc. Mr. Anderson also held the position of Chief Financial Officer and Secretary at Clearant, Inc., a biotechnology company, and was CFO and Managing Director of Intellect Capital Group, a venture consulting firm.
Omar Manejwala, M.D., Chief Medical Officer
Dr. Omar Manejwala is recognized as a leading expert in behavior change, with a career focused on developing, piloting, and commercializing scalable solutions that promote durable behavior change in chronic diseases. Before joining DarioHealth, he served as the Chief Medical Officer of Catasys Inc. At Catasys, he was instrumental in leading product development from inception to commercial scale, securing contracts with many of the largest U.S. health plans, and contributing to the company's growth to an approximate $1.5 billion valuation at its peak. Dr. Manejwala is a Distinguished Fellow of the American Psychiatric Association, a Fellow of the American Society of Addiction Medicine, and the author of the best-selling book "Craving: Why We Can't Seem to Get Enough."
Steven Nelson, President & Chief Commercial Officer
Steven Nelson is responsible for developing and executing strategies to drive rapid commercialization at DarioHealth, overseeing global commercial activities including growth strategy, sales, client management, marketing, strategic partnerships, and market expansion. He possesses over two decades of experience in building and scaling technology-centric healthcare companies. Most recently, Mr. Nelson was the Chief Executive Officer and President of Contigo Health, where he successfully scaled the company's revenue, achieved profitability, managed over 75 clients, and established numerous national and regional health plan and employer partnerships.
AI Analysis | Feedback
The key risks to DarioHealth's (DRIO) business are primarily centered around its financial viability, intense market competition, and the evolving regulatory and operational landscape.
- Financial Stability and Going Concern: DarioHealth has reported significant operating losses and an accumulated deficit, reaching approximately $390.3 million as of December 31, 2024. The company has not yet achieved profitability. Management has disclosed substantial doubt about DarioHealth's ability to continue as a going concern, indicating that current cash resources are insufficient for a full year of operations. The company also faced a breach of a financial covenant under a credit agreement as of June 30, 2025, with a waiver granted conditional on an equity cure by November 15, 2025.
- Market Competition and Revenue Challenges: The digital health market in which DarioHealth operates is highly competitive, making it challenging for the company to secure and maintain a substantial market share. Analysts have downgraded revenue estimates for DarioHealth, projecting slower revenue growth compared to the broader industry. The company's ability to expand its customer base and enhance its digital health engagement platform is crucial for market penetration and revenue growth.
- Regulatory Compliance and Customer Concentration: DarioHealth must navigate a complex and evolving regulatory environment to obtain and maintain marketing authorizations for its products. This includes complying with cybersecurity requirements for medical devices, which can lead to increased costs and operational hurdles. Additionally, the company faces operational risks due to a degree of customer concentration; as of December 31, 2024, one major customer accounted for 41.6% of accounts receivable, although this percentage decreased to 16.4% by June 30, 2025. The loss of a significant customer could materially impact revenue.
AI Analysis | Feedback
There are two clear emerging threats for DarioHealth:
Entry and Expansion of Large Technology Companies: Major tech players like Amazon, Google, and Apple are increasingly entering and expanding their presence in the healthcare and digital health sectors. Amazon, with its Amazon Clinic and Amazon Pharmacy, shows a clear intent to provide integrated healthcare services. Should these companies leverage their vast resources, existing customer bases, and technological prowess to offer comprehensive chronic condition management platforms (potentially bundling devices, coaching, and virtual care at scale), they could significantly disrupt or marginalize specialized digital health providers like DarioHealth. This mirrors the historical threat posed by new, powerful entrants with broad ecosystems.
Market Consolidation and Demand for Integrated Platforms: The digital health market is undergoing significant consolidation, with employers and health plans increasingly prioritizing integrated, multi-condition platforms over fragmented point solutions. The merger of Teladoc and Livongo is a prime example of this trend, creating a more comprehensive virtual care and chronic condition management offering. This trend puts pressure on companies like DarioHealth to compete against larger, more integrated platforms that can offer a broader suite of services under a single vendor, potentially leading to increased competition for partnerships and market share.
AI Analysis | Feedback
DarioHealth Addressable Markets
DarioHealth (symbol: DRIO) offers an integrated digital therapeutics platform and solutions for managing several chronic conditions. The addressable markets for their main products and services are primarily focused on metabolic health (diabetes, hypertension, weight management), musculoskeletal health, and behavioral/mental health. Here are the estimated addressable market sizes for DarioHealth's main products and services:- Digital Therapeutics (Overall): The global addressable market for digital therapeutics is approximately $108 billion. In the U.S. alone, this market is estimated at $72 billion annually.
- Diabetes Management:
- The U.S. diabetes market for monitoring, treatment, and drug delivery was valued at nearly $48 billion in 2024 and is projected to reach $79 billion by 2031.
- The U.S. digital diabetes management market size was valued at $3.92 billion in 2024 and is expected to reach $17.23 billion by 2033.
- The U.S. diabetes devices market was valued at $9.53 billion in 2023 and is expected to reach $15.21 billion by 2030.
- The North America diabetes care industry is estimated at $34.51 billion in 2025 and is expected to reach $62.73 billion by 2032.
- Hypertension Management:
- The U.S. pain management market, which includes musculoskeletal pain, was valued at $31.80 billion in 2024 and is estimated to reach $32.79 billion in 2025, projected to grow to $43.58 billion by 2033.
- North America held a major share of the global Hypertension Management Devices market, with a market size of $2.073 billion in 2024. The U.S. alone had a market size of $1.6356 billion in 2024 for hypertension management devices.
- The global antihypertensive drugs market is forecast to grow from $25.50 billion in 2025 to $35.99 billion by 2034. North America dominated this market with a 38% revenue share in 2024.
- Weight Management:
- The U.S. weight loss and obesity management market size is likely to be valued at $5.5 billion in 2025 and is expected to reach $7.5 billion by 2032.
- The U.S. weight management market size was estimated at $37.86 billion in 2023 and is expected to grow to $76.9 billion by 2030.
- The global weight management market size is calculated at $163.13 billion in 2024 and is expected to be worth $362.1 billion by 2034. North America led the global weight management market in 2024 with a revenue of $84.5 billion.
- Musculoskeletal (MSK) Health:
- The U.S. pain management market was valued at $31.80 billion in 2024 and is estimated to reach $32.79 billion in 2025, projected to grow to $43.58 billion by 2033. The musculoskeletal pain segment held 41.2% of the U.S. pain management market share in 2024.
- The global musculoskeletal disorders treatment market is anticipated to grow from $209.01 billion in 2025 to $353.12 billion by 2034. North America reported being the largest region with a 37% market share in 2023.
- The musculoskeletal pain market across the top 7 markets (US, EU4, UK, and Japan) reached a value of $4.0878 billion in 2024 and is expected to reach $5.7579 billion by 2035. The United States has the largest patient pool for musculoskeletal pain and also represents the largest market for its treatment.
- Behavioral/Mental Health:
- The U.S. behavioral health market size was valued at $92.2 billion in 2024, is expected to reach $96.9 billion in 2025, and is projected to hit $151.62 billion by 2034.
- Another estimate values the U.S. mental health market size at $110 billion in 2024, expected to reach $132 billion by 2033.
- The U.S. behavioral health market size was valued at $87.82 billion in 2024. It is projected to grow from $92.14 billion in 2025 to $132.46 billion by 2032.
- The North America behavioral health market size is calculated at $109.21 billion in 2024, grew to $115.65 billion in 2025, and is projected to reach around $193.03 billion by 2034.
AI Analysis | Feedback
```htmlExpected Drivers of Future Revenue Growth for DarioHealth (DRIO)
-
Expansion of B2B Footprint and Recurring Revenue: DarioHealth is focused on expanding its business-to-business (B2B) sales by targeting employers, health plans, and providers. This strategy aims to establish more stable, recurring revenue streams through new client acquisitions and the expansion of existing contracts for its digital health solutions.
-
Diversification into Multiple Chronic Conditions: The company has strategically broadened its platform beyond diabetes management to include solutions for hypertension, weight management, musculoskeletal (MSK) conditions, and mental health. This expansion into a multi-condition platform increases its total addressable market and allows it to offer a more comprehensive suite of services to clients.
-
Integration of the Twill Acquisition and Strategic Partnerships: The acquisition of Twill in 2024 significantly expanded DarioHealth's capabilities, particularly in mental health and chronic condition management, which is expected to drive revenue through cross-selling opportunities and a broader product portfolio. Strategic collaborations, such as the one with OneStep for integrating fall risk assessment technology, also contribute to market expansion.
-
Launch and Expansion of GLP-1 Offering: DarioHealth has introduced and is expanding its GLP-1 product offering, which includes virtual prescribing and integration into its chronic condition management programs. This is identified as a key priority to accelerate growth.
-
Leveraging AI for Personalized Interventions and Operational Efficiency: The company is investing in and applying artificial intelligence (AI) to enhance personalized guidance, automate workflows, optimize cost structures, and improve operational scalability. This AI-driven approach aims to deliver better clinical outcomes and user engagement, attracting more clients to its platform.
AI Analysis | Feedback
Share Issuance
- In February 2021, DarioHealth closed a registered direct offering of 3,278,688 shares of common stock at a purchase price of $21.35 per share, generating aggregate gross proceeds of $70,000,000.
- In late 2024 and early 2025, the company completed a $25.6 million private placement of convertible preferred stock.
- By the end of Q2 2025, DarioHealth completed an oversubscribed $17.5 million private placement, increasing its pro forma cash position to approximately $40 million.
Inbound Investments
- DarioHealth completed a $25.6 million private placement of convertible preferred stock in late 2024 and early 2025, with significant participation from existing shareholders and accredited healthcare investors.
- In September 2025, the company completed an oversubscribed $17.5 million private placement.
Outbound Investments
- DarioHealth acquired Upright for $31 million in January 2021.
- In May 2021, the company acquired wayForward for aggregate consideration of $6.0 million in cash and up to $24.0 million in shares of common stock.
- DarioHealth acquired Twill for $10 million in February 2024.
Capital Expenditures
- In the last 12 months as of October 2025, DarioHealth reported capital expenditures of approximately $128,000.
Trade Ideas
Select ideas related to DRIO. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for DarioHealth
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.6% |
| Rev Chg 3Y Avg | 2.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 12.1% |
| Op Mgn 3Y Avg | 11.9% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Price Behavior
| Market Price | $10.04 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/09/2013 | |
| Distance from 52W High | -67.2% | |
| 50 Days | 200 Days | |
| DMA Price | $12.78 | $12.50 |
| DMA Trend | down | up |
| Distance from DMA | -21.4% | -19.7% |
| 3M | 1YR | |
| Volatility | 106.8% | 2,037.9% |
| Downside Capture | 230.56 | 305.38 |
| Upside Capture | 50.47 | 228.89 |
| Correlation (SPY) | 17.8% | 2.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.16 | 1.66 | 0.87 | 9.64 | 2.21 | 1.78 |
| Up Beta | -1.15 | 2.21 | 1.32 | -35.58 | -4.22 | -1.85 |
| Down Beta | 17.56 | 2.25 | 3.42 | 1.98 | 0.83 | 1.36 |
| Up Capture | -128% | -18% | 54% | 3130% | 576% | 158% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 9 | 15 | 26 | 50 | 112 | 339 |
| Down Capture | 43% | 235% | -81% | 412% | 159% | 111% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 10 | 26 | 36 | 74 | 134 | 392 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of DRIO With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| DRIO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -37.3% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 2,021.8% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | 0.95 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | -2.4% | 2.0% | 3.2% | 4.5% | -1.6% | 3.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of DRIO With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| DRIO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -47.9% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 909.0% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | 0.39 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 0.3% | 3.1% | 2.9% | 2.3% | 1.1% | 2.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of DRIO With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| DRIO | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -39.9% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 653.1% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.28 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 1.3% | 3.2% | 2.8% | 2.2% | 1.8% | 2.0% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/24/2023 | -12.8% | -11.6% | -35.7% |
| 2/6/2023 | 10.5% | 8.2% | -5.1% |
| 8/15/2022 | -5.9% | -31.6% | -42.6% |
| 1/19/2022 | -3.3% | -13.7% | -11.6% |
| 8/16/2021 | -12.3% | -5.1% | 5.6% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 4 | 4 | 4 |
| Median Positive | 10.5% | 8.2% | 5.6% |
| Median Negative | -9.1% | -12.7% | -23.7% |
| Max Positive | 10.5% | 8.2% | 5.6% |
| Max Negative | -12.8% | -31.6% | -42.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11132025 | 10-Q 9/30/2025 |
| 6302025 | 8122025 | 10-Q 6/30/2025 |
| 3312025 | 5142025 | 10-Q 3/31/2025 |
| 12312024 | 3102025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8082024 | 10-Q 6/30/2024 |
| 3312024 | 5152024 | 10-Q 3/31/2024 |
| 12312023 | 3282024 | 10-K 12/31/2023 |
| 9302023 | 11022023 | 10-Q 9/30/2023 |
| 6302023 | 8102023 | 10-Q 6/30/2023 |
| 3312023 | 5112023 | 10-Q 3/31/2023 |
| 12312022 | 3092023 | 10-K 12/31/2022 |
| 9302022 | 11142022 | 10-Q 9/30/2022 |
| 6302022 | 8152022 | 10-Q 6/30/2022 |
| 3312022 | 5122022 | 10-Q 3/31/2022 |
| 12312021 | 3222022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Nelson Steven Charles | President and CCO | 8272025 | Buy | 0.53 | 40,000 | 21,200 | 50,350 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.